The performance of Cadila Healthcare, so far in the current year has been modest. It has been able to log less than 7% growth in topline for the first half of the current year. However, the company is on an acquisition spree to log faster growth through in-organic route.
Recently, Cadila acquired Indiaís No.1 Cardiovascular product ĎAtení from Kopran for a total consideration of Rs 950 m. On last count ĎAtení had revenues in excess of Rs 380 m, logging a growth of more than 12% p.a. with more than 20% market share. The purchase of ĎAtení coupled with new product introductions in its newly commissioned Zydus Neuroscience division puts the company in the league of leading cardiovascular companies in India.
Zydus Neuroscience division has launched more than 8 products in the first half of the current year itself. Further, the company would also benefit from its acquisition of perpetual rights to market five leading brands from Asta (one of the promoters of German Remedies)
Cadila is also logging several co-marketing alliances to offer a better basket of products. It has already entered into several co-marketing alliances with Kopran, Ranbaxy and E-Merck for some of the drugs in therapeutic segments of anti-diabetics, CNS and other high growth segments. Remarkably, Cadila launched Once-a-Day version of Ofloxacin drug in alliance with Ranbaxy.
Further the acquisition of 28% stake in German Remedies last year is also expected to help the company in leveraging entry in to high margin therapeutic segments like respiratory, gynaecology and oncology, where German Remedies has a strong presence.
At the current market price of Rs 131, the stock is valued at 8 times FY02 expected earnings. These acquisitions are expected to help Cadila in logging faster growth rates going forward. However, the concern is the financing of these ventures may put an undue strain on the companyís balance sheet. The prospects of the company would depend on how fast the ambitious acquisitions pays off and performance of its new product introductions.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407